Navigation Links
Vitamin B-based treatment for corneal disease may offer some patients a permanent solution
Date:10/24/2011

ORLANDO, Fla. October 24, 2011 Patients in the United States who have the cornea-damaging disease keratoconus may soon be able to benefit from a new treatment that is already proving effective in Europe and other parts of the world. The treatment, called collagen crosslinking, improved vision in almost 70 percent of patients treated for keratoconus in a recent three-year clinical trial in Milan, Italy. The treatment is in clinical trials in the United States and is likely to receive FDA approval in 2012. The results of the Milan study are being presented today at the 115th Annual Meeting of the American Academy of Ophthalmology in Orlando, Florida.

In a session titled Long-term Results of Corneal Crosslinking for Keratoconus, Paolo Vinciguerra, MD will describe the treatment and three-year follow up of more than 250 keratoconus patients who received collagen crosslinking at his clinic. Sixty-eight percent of the 500 eyes treated gained significant visual acuity, with their results remaining stable at the end of the follow-up period. Patients over age 18 were most likely to improve.

In the collagen crosslinking procedure, riboflavin (vitamin B) is applied to the cornea, which is then exposed to a specific form of ultraviolet light. Collagen fibers regenerate with new bonds forming between them, increasing corneal stiffness and strength. The treatment also combats the causes of keratoconus, reducing the chance that it will recur. The rest of the eye receives only minimal UV exposure during treatment. Dr. Vinciguerra's new study confirms that adverse effects are rare. Previous research by his team indicated no loss of corneal endothelial cell, a measurement used to assess the safety of corneal treatments, in patients who received collagen crosslinking.

"For many people with keratoconus, collagen crosslinking can provide a better and more permanent solution to their vision problems," said Dr. Vinciguerra. "Given that no current treatment in use in the U.S. offers permanent correction, this effective option represents a significant advance for corneal medicine."

One in 2,000 people in the United States and worldwide are diagnosed with keratoconus, a disease that damages the collagen fibers that form the structure of the cornea, which is the outer surface of the eye. The cornea's crucial task is to focus, or "refract," incoming light toward the eye's lens. To perform properly, the cornea needs to be rounded, like the surface of a ball. As keratoconus worsens and the cornea becomes thinner, it may bulge outward in a cone shape, causing nearsightedness and/or astigmatism, making clear vision impossible. As the number of fibers and links between them decline, the cornea loses up to 50 percent of its normal stiffness.

Standard treatments in the U.S., such as specialized eyeglasses, contact lenses, or implanted lenses, cannot permanently correct keratoconus, and none of these treatments address the underlying causes. Severe keratoconus often requires corneal transplant.


'/>"/>

Contact: Mary Wade
mwade@aao.org
510-725-5677
American Academy of Ophthalmology
Source:Eurekalert  

Related medicine news :

1. Women do not get enough vitamin D during the menopause
2. Research Sheds Light on Vitamin Ds Role in Immunity
3. Extra Vitamin E May Be Associated With Prostate Cancer
4. National study finds vitamin E supplement may increase prostate cancer risk
5. Oral steroids linked to severe vitamin D deficiency in nationwide study
6. Could Too Little Vitamin B-12 Shrink the Aging Brain?
7. Many Black Men in Cold Climates Lack Vitamin D
8. Vitamin D deficiency linked with airway changes in children with severe asthma
9. African-American men living in poor sunlight areas at risk for vitamin D deficiency
10. One size doesnt fit all for vitamin D and men
11. Confirmation that vitamin D acts as a protective agent against the advance of colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vitamin B-based treatment for corneal disease may offer some patients a permanent solution
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first ... patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved ... be the first in Arkansas to introduce the most powerful SCS system and the ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... foods, is sharing bold recipes for Memorial Day entertaining that are sure to ... , “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly balanced ...
(Date:5/26/2017)... MD (PRWEB) , ... May 26, 2017 , ... After ... anti-stress Antzy Top gadget will continue to be available at a discounted crowdfunding price ... deal with stress wherever they are, I also wanted to bring a fidget toy ...
(Date:5/26/2017)... ... 26, 2017 , ... Rob Lowe acts as host and helps educate and ... on hiking in American. Viewers can reconnect with America as it explores some of ... Many consumers have looked for an inventive new place for a family vacation, and ...
(Date:5/26/2017)... ... ... the Cross”: the personal journey of Bob Massey and his faith in the Lord. ... Margaret Massey. Bob Massey is small in stature but big in character. As ... for others is apparent in all of his life decisions. , “I’m in the ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 CSSi, the global ... the clinical research industry, is proud to announce the ... The new website features both enriched content and a ... and enhances the company,s already well-established position as the ... "After many months of hard work, we ...
(Date:5/9/2017)... WASHINGTON , May 9, 2017  Demonstrating ... the board of directors for the Pharmaceutical Research ... criteria for membership. Biopharmaceutical companies will now have ... in order to be eligible to join PhRMA. ... criteria, the board is sending a clear message ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
Breaking Medicine Technology: